Hanmi Pharmaceutical Selected as Research Institution for National Project to Build AI New Drug Development Platform

Development and Implementation of "Reverse Translational Research Design AI Software"

Hanmi Pharmaceutical has been selected as a key research institution for a government-led national project aimed at establishing a domestic artificial intelligence (AI) end-to-end new drug development ecosystem.

On November 7, Hanmi Pharmaceutical announced that it has been designated as a joint research institution participating in the new project for the "2025 K-AI Preclinical and Clinical Model Development Project for New Drug Development," which is overseen by the Ministry of Health and Welfare.

Exterior view of Hanmi Pharmaceutical R&D Center in Hwaseong-si, Gyeonggi-do. Hanmi Pharmaceutical

The objective of this project is to build a multimodal preclinical and clinical dataset for new drug development, with the main focus on developing "reverse translational research design AI software" that can integrate and analyze both preclinical and clinical data. Reverse translational research refers to an approach that feeds data obtained from clinical trials back into the preclinical stage, thereby improving the accuracy and efficiency of new drug development.

The project will be conducted as a multicenter joint research initiative involving domestic hospitals, pharmaceutical companies, and academia. Hanmi Pharmaceutical will participate as a joint institution in the "reverse translational research design AI software development" field, led by Samsung Medical Center. The consortium includes Samsung Medical Center (lead), Kangbuk Samsung Hospital (joint), Hanmi Pharmaceutical, and other major pharmaceutical companies, all working together to build the AI new drug development ecosystem.

In this project, Hanmi Pharmaceutical will provide data accumulated through years of new drug research in the fields of oncology and metabolic diseases, and will also play a role in generating new preclinical multimodal data. To this end, Hanmi Pharmaceutical plans to actively utilize its proprietary new drug development capabilities, including cell-based (in vitro) experiments, animal model (in vivo) tissue analysis, and omics (genomics, proteomics, etc.) data.

Hanmi Pharmaceutical intends to implement the AI software developed through this project at an early stage, applying and validating AI-generated hypotheses or novel candidate substances in the actual new drug research process, and feeding the results back into AI training to establish a virtuous research cycle.

The AI software, developed by integrating data from multiple institutions, is expected to reduce uncertainties in the clinical phase and, by significantly enhancing the accuracy and predictive power of preclinical models in future new drug development, substantially increase the likelihood of clinical trial success.

Choi Changjoo, Head of Research at Hanmi Pharmaceutical (Executive Director), stated, "It is meaningful that Hanmi Pharmaceutical can contribute to the advancement of the domestic AI new drug development ecosystem by participating as a core joint institution in the K-AI national project. We will make every effort to leverage the data held by each institution to successfully bridge preclinical and clinical stages, and ultimately strengthen the nation's capabilities for innovative new drug development."

This content was produced with the assistance of AI translation services.